Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ask already at .80 premarket. Could see $1+ today! Let's test new highs.
Shares Float 14,328,740
Total Shares Outstanding 96,451,503
% Owned by Insiders 85.10 %
% Owned by Institutions %
Market Cap. $ 67,516,052
Trading Volume - Today 2,274,472
Trading Volume - Average 86,900
Trading Volume - Today vs. Average 2617.34 %
Earnings Per Share -0.16
PE Ratio
Record Date 2009-DecB
http://www.shortsqueeze.com/?symbol=bvti
o/s 96.45M according to company website http://biovest.com/investors.html
Anyone know what the share structure is?
what do you mean? I'm new in the stock market
I thank everybody busy with the solid news and trying to read between the lines.
Where is everyone? What happened to the volume today? Anyone hear anything about any news? TIA.
If you look at some of the other cancer immunotherapy stocks they range from 3.00 up to about 23.00. BVTI hit 1.50 in July on news of Phase 3 results. Once the BLA gets aproved this thing will not go below 1.00 again.
the last 2 times this stock popped up big like today, it gapped and ran the next day...hopeing history repeats!!
dip should be .80 then its boom
im still on the fence on this one hope im not oo late, i probably buy the next dip?
i got in at .55, i think this will run some more tomorow. read the news carefully, its very juicy :)
BVTI double bottom off .78 on the intraday. power hour coming
any one real quick got in at .52 with news whats up
bought in on the news. $1 plus by day's end
is there a good fda approval board on IHUB?
little conso. after that will go uppppppp.....
come may this can be as much as $ 5 buck load up. it will fly when dndn is aproved for provenge. DNDN will be the first cancer vaccine approved by the FDA. So its only right that related companies ride the momentum as well. got my lil shares ready.
good luck.
here we gooooo i'm in.....
Chartbreaker1
WOW, great news. ABPIQ owns 81% of BVTI.
BVTI jumped almost 85% in last two trading sessions with good volume
BVTI in Pharma Voice Magazine - Research Report
http://www.box.net/shared/2t72oun7iy
BVTI - July 6,2009 - Therapeutic cancer vaccines show promise - Published in LA Times
They wouldn't prevent the disease, but might help people who are already fighting it.
By Jill U. Adams >>>
July 6, 2009
It's a deceptively simple idea: What if doctors could recruit the body's own immune system to fight cancer? The complexities of the immune system have kept this from becoming reality, until now. Three cancer vaccines -- for prostate cancer, melanoma and lymphoma -- have achieved positive results in so-called Phase 3 clinical trials -- the kind of studies that the Food and Drug Administration requires for a medicine to gain approval.
At the annual meeting of the American Society of Clinical Oncology held May 29 to June 2, researchers reported that a vaccine against follicular lymphoma, called BiovaxID, delayed remission after chemotherapy by more than one year, on average.
At the same meeting, other researchers said that a melanoma vaccine caused tumors to shrink in twice as many patients as those receiving a standard FDA-approved therapy.
And at the annual meeting of the American Urological Assn. in April, researchers reported that the vaccine Provenge extended the lives of men with metastatic prostate cancer by four months, on average.
Doctors are cautiously optimistic about the news. "Researchers have been working very hard to get some positive results," says Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society in Atlanta. "These three trials do suggest that vaccines will be used in the actual treatment of patients in the not too distant future."
But even with these tentative successes, a big question remains open: Will vaccines ever become more than small players in the medical treatment of cancer -- a group of diseases that presently kills some 560,000 Americans each year?
Only two cancer vaccines currently have FDA approval and both are strictly preventive, targeting viruses that can lead to cancer. Most U.S. children are vaccinated against hepatitis B, a virus that can cause liver disease and cancer. A vaccine for genital human papillomavirus (HPV), which can cause genital warts and cervical cancer, is now recommended for adolescent girls.
The new medicines -- called therapeutic cancer vaccines -- act differently. They are not preventive in the traditional concept of vaccines. Rather, patients already afflicted with cancer are vaccinated in the hope that the shots will tell their immune systems how better to fight growing tumors. And because the immune system has a long memory, it's hoped that this immune boost might also ward off cancer recurrences.
Researchers have been working on the strategy for at least four decades and have suffered many failures, even in vaccines that showed promise in Phase 1 and Phase 2 clinical trials, which test safety and effectiveness of experimental treatments in a small number of patients. "It's been a really frustrating journey for a lot of researchers," Lichtenfeld says. "A lot of hope and a lot of dashed hopes, unfortunately."
Basic research on the immune system in the last 10 to 15 years has led to an explosion of new knowledge about the intricacies of the immune system -- and some clues as to why these early strategies failed. For instance, it's now known that tumors can shut down immune activity in their vicinity. The three new vaccines, as well as many more under development, have incorporated past lessons and new knowledge to improve their odds.
Generally, vaccines are made from a substance that only cancer cells make (or that they make far more of than normal cells do) -- say, a protein that sits on the surface of a tumor cell. Then the vaccine is injected into the body. If the immune system senses that the substance is a foreign invader, then it starts to ramp up a response. The mechanisms vary, but essentially the body makes new immune cells and sends them out on search-and-destroy missions, seeking out anything that contains that same substance, or marker.
In the past, small protein fragments -- called antigens -- that are present in high amounts on cancer cells were used in cancer vaccines. But the ones that were chosen did not stimulate enough of an immune response to attack tumors effectively.
"We know a lot about tumor antigens," says Dr. Leisha Emens, an oncologist at Johns Hopkins University who is researching breast cancer vaccines. "I don't think we've done that great of a job identifying which ones are the most important."
You don't want just any immune response, you want one that will effectively attack the cancer cells, she says.
Dr. Donald Morton, chief of the melanoma program at the John Wayne Cancer Institute in Santa Monica, tells a cautionary tale. He led a different melanoma vaccineall the way through to a Phase 3 clinical trial. With 1,600 patients worldwide, it was much larger than the recent crop of studies. Morton says the rate of survival in the study was the highest he'd ever seen. However, that rate did not differ from the control group, who received only an immune stimulant, and the trial was halted in 2006. "There's no question that some patients responded to the vaccine," he says, based on a review of the data. However, many more patients did not.
The three vaccines with recent success don't work in all patients either, even though researchers tried to define patient populations that would be most amenable to vaccine therapy. In the melanoma vaccine trial, only patients with certain tissue types -- akin to tissue-typing for organ transplantation -- were included.
In the lymphoma vaccine trial, only patients who responded to chemotherapy and remained in remission for six months were eligible to receive the vaccine.
The vaccines don't measure up to other cancer therapies that have passed muster with the FDA in recent years, such as Herceptin, Gleevec and Rituxan, says Dr. John Glaspy, director of the Women's Cancers Program at UCLA's Jonsson Comprehensive Cancer Center. Gleevec, in particular, has revolutionized the care of the most common adult leukemia, known as chronic myeloid leukemia, raising five-year survival rates to 89% of patients taking the drug. Before Gleevec, patients' chances of surviving for five years with existing treatments were closer to 50%. "Those are huge breakthroughs in oncology that have made big impacts," Glaspy says.
Cancer vaccines have made comparable advances on the basic science front, but they have not yet translated into successful medicines. Yet researchers are reinvigorated by the recent successes because they suggest that, with combination therapies and careful patient selection, the vaccine strategy could work to fight cancer. "It's feasible," Glaspy says. "We're starting to see a few patients do well."
The ideal of therapeutic cancer vaccines still shimmers with promise: Imagine a medicine that's specific to a tumor and free of side effects. "If we can get the immune system to engage in this process, it works completely differently than any other cancer treatment out there. And the neat thing about the immune system is that it remembers," Emens says. "If we can get it to work, it has the potential to add a lot."
Even those stung with failure hold onto hope. "I remained convinced that the immune system is very important in the control of cancer," Morton says. "We just need to know what the right buttons are to push so that everybody responds."
health@latimes.com
http://www.latimes.com/features/health/la-he-cancervaccines6-2009jul06,0,6487100.story
Yes that was nice news here.
BVTI moving up nicely, consolidation in works
Biovest has already launched BiovaxID in Europe on named-patient basis last week and we are looking for some solid revenue numbers.
Charts added to IBOX !
BVTI Revenue Projection
http://sec.gov/Archives/edgar/data/704384/000119312506152662/dex991.htm
Move to Slide # 10 for details
Biovest launches BiovaxID in Europe on named-patient
http://www.tradingmarkets.com/.site/news/Stock%20News/2396852/
Great NEWS ----> This will move quite nicely.
Biovest launches BiovaxID in Europe on named-patient
http://www.tradingmarkets.com/.site/news/Stock%20News/2396852/
Expected more volume activity today from the news this morning.
Took a starter position here with 30k shares at $0.46 per share avg.
Quite bullish with that news this morning. Chart is looking awfully nice as well.
BVTI up 29% today
More UPDATES expected real soon here with BVTI.
Thanks for all the info...
"BVTI plan to make BiovaxID available throughout most of Europe on a named-patient basis. This compassionate-use drug access program allows European physicians to prescribe drugs to qualifying patients before approvals are granted, assuming the protocols for each participating country are followed."
Float is real thin here.
Nice, just looked at the PPT presentation, so 56% is held by accentia ? Wonder how thin the float might be if you say many are in strong hands...
Do you have more info about that ?
YES, many are long term investors, so they are not concerned about the current price. Although, BVTI is doing much behind the scene, another major pharma partner in USA or takeover is in works.
Just went through filings quick..can it be that people bought shares at much higher prices ?
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
320
|
Created
|
01/27/06
|
Type
|
Free
|
Moderators |
http://www.biovest.com
Biovest International Inc, is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically-integrated specialty biopharmaceutical company with services to commercialize targeted therapeutics. Accentia is a publicly traded company (NASDAQ: ABPI) that has a product portfolio featuring targeted therapeutics, specialty sales and marketing, pharmacoeconomic services, product development, and specialty distribution.
Biovest has a deep foundation in the manufacture of biological drugs from small research scale quantities to large volumes for Phase I and Phase II clinical material. In addition, Biovest International develops, manufactures, and markets patented cell culture systems and equipment to pharmaceutical, diagnostic and biotechnology companies, as well as leading research institutions worldwide. For over 10 years the company has operated the National Cell Culture Center (NCCC) under a grant from the National Institutes of Health.
Biovest is the holder of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for the commercialization of BiovaxID, a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin's lymphoma. This therapy, referred to as BiovaxID, is currently in a phase 3 pivotal trial at 24 major medical institutions in the US.
SEC FILINGS
http://phx.corporate-ir.net/phoenix.zhtml?c=154286&p=irol-sec
RECENT NEWS
http://finance.yahoo.com/q?s=BVTI.OB
DAILY CHART
WEEKLY CHART
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |